Stock Events

Stock Events

Krystal Biotech 

€219.2
0
-€0.6-0.27% Friday 19:55

Statistics

Day High
219.7
Day Low
216.5
52W High
250.3
52W Low
108.1
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4KB.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abeona Therapeutics
ABEO
Mkt Cap274.98M
Abeona Therapeutics focuses on developing gene and cell therapies for life-threatening diseases, similar to Krystal Biotech's gene therapy approach.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same innovative treatment space as Krystal Biotech.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including gene therapies.
Pfizer
PFE
Mkt Cap161.09B
Pfizer, through its acquisition of Bamboo Therapeutics, has ventured into gene therapy, making it a competitor with its vast resources.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals, with its CRISPR and gene editing ventures, represents a broader competitor in the genetic treatment landscape.
Novartis
NVS
Mkt Cap297.32B
Novartis has made significant investments in gene therapy, including the acquisition of AveXis, positioning it as a major player in the field.

About

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Show more...
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Employees
275
Country
US
ISIN
US5011471027

Listings

MI
IT
1KRYS.MI
XNAS
US
KRYS
SA
BR
K1YS34.SA
STU
DE
4KB.STU

0 Comments

Share your thoughts

FAQ

What is Krystal Biotech stock price today?▼
The current price of 4KB.STU is €219.2 EUR — it has decreased by -0.27% in the past 24 hours. Watch Krystal Biotech stock price performance more closely on the chart.
What is Krystal Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Krystal Biotech stocks are traded under the ticker 4KB.STU.
Is Krystal Biotech stock price growing?▼
4KB.STU stock has fallen by -2.19% compared to the previous week, the month change is a +0.5% rise, over the last year Krystal Biotech has showed a +50.55% increase.
How many employees does Krystal Biotech have?▼
As of April 11, 2026, the company has 275 employees.
In which sector is Krystal Biotech located?▼
Krystal Biotech operates in the Health Care sector.
When did Krystal Biotech complete a stock split?▼
Krystal Biotech has not had any recent stock splits.
Where is Krystal Biotech headquartered?▼
Krystal Biotech is headquartered in Pittsburgh, US.